SEC Comment Letter for Tvardi Therapeutics, (TVRD) — May 7, 2026
Tvardi Therapeutics, Inc.
Date: May 7, 2026 · CIK: 0001346830 · Accession: 0000000000-26-004698
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-295496
Letter
Re: Tvardi Therapeutics, Inc. Registration Statement on Form S-3 Filed May 1, 2026 File No. 333-295496 Dear Imran Alibhai:
May 7, 2026
Imran Alibhai Chief Executive Officer Tvardi Therapeutics, Inc. 3 Sugar Creet Ctr. Blvd. Suite 525 Sugar Land, TX 77478
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jessica Dickerson at 202-551-8013 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Madison A. Jones, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> May 7, 2026 Imran Alibhai Chief Executive Officer Tvardi Therapeutics, Inc. 3 Sugar Creet Ctr. Blvd. Suite 525 Sugar Land, TX 77478 Re: Tvardi Therapeutics, Inc. Registration Statement on Form S-3 Filed May 1, 2026 File No. 333-295496 Dear Imran Alibhai: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Madison A. Jones, Esq. </TEXT> </DOCUMENT>